JP Patent

JP6636933B2 — Ｒｏｓ１変異癌細胞を有する患者を治療するための化合物

Assigned to イグナイタ インコーポレイテッド · Expires 2020-01-29 · 6y expired

What this patent protects

Patent listed against Rozlytrek.

Drugs covered by this patent

Patent Metadata

Patent number
JP6636933B2
Jurisdiction
JP
Classification
—
Expires
2020-01-29
Drug substance claim
No
Drug product claim
No
Assignee
イグナイタ インコーポレイテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.